Natco Pharma gains on launching Nexavar in US mkt

Image
Capital Market
Last Updated : Jun 01 2022 | 12:17 PM IST

Natco Pharma rose 3.09% to Rs 713.45 after the company announced the launch of first generic version of Nexavar (Sorafenib) tablets in the US market.

Viatris, a global pharma company and commercial partner of Natco, will launch the product.

Sorafenib is prescribed for treatment of unresectable Hepatocellular Carcinoma (HCC), advanced Renal Cell Carcinoma (RCC) and Differentiated Thyroid Carcinoma (DTC). It is an oral multi-kinase inhibitor that is used in the therapy of advanced renal cell, liver and thyroid cancer.

As per the industry sales data, Nexavar registered sales of $69.7 million for the year ended December 2021.

Natco Pharma is a vertically integrated and R&D focused pharmaceutical company engaged in developing, manufacturing and marketing of finished dosage formulations and active pharmaceutical ingredients.

On a consolidated basis, net profit of Natco Pharma tumbled 195.3% to Rs 50.5 crore despite of 80.1% rise in net sales to Rs 596.80 crore in Q4 FY22 over Q4 FY21.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jun 01 2022 | 11:44 AM IST

Next Story